GLP-1 maintenance claims on TikTok: what holds up?

What did @mariahhopkins_ actually say?

She laid out her personal semaglutide maintenance strategy after hitting her goal weight: tapering back to her starting dose, then stretching injection intervals from every 7 days to every 10, then every 14 days. She also made a broader claim that "the majority of people that get off the medication as soon as they lose their weight will gain their weight back." She was careful to say she's not a doctor and can't tell you what to do. That disclaimer matters, but it doesn't fully neutralize the risk of 35,000 viewers copying her interval-extension approach without medical supervision.

She also argued that providers aren't talking enough about maintenance, and that insurance coverage complicates staying on these drugs long-term. Both of those points are hard to argue with.

Does the science back this up?

The weight regain claim is the most well-supported thing she said. The evidence here is fairly damning. In the STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine), participants who stopped semaglutide regained about two-thirds of their lost weight within a year. That's not a fringe finding, it's a core result from the trial that put semaglutide on the map for obesity.

The trickier question is her dose-tapering and interval-stretching approach. Semaglutide has a half-life of roughly one week, which is why it's dosed weekly. Stretching to 10 or 14 days means plasma concentrations will drop between injections in ways that aren't studied in any published maintenance trial. There is no peer-reviewed evidence that extended dosing intervals maintain body weight over time. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed sustained weight loss with continuous weekly dosing for two years, but that's a different protocol entirely. Her personal success at 5 months is anecdotal, not evidence.

What did they get wrong (or right)?

She got the big picture right: weight regain after stopping GLP-1 medications is real, common, and under-discussed. Providers genuinely do a poor job of preparing patients for what happens after the weight loss phase. Full credit there.

What she got wrong, or at least dangerously incomplete, is presenting her personal interval-extension schedule as a viable template. Stretching from weekly to biweekly injections isn't a validated maintenance strategy. It's an experiment she ran on herself. Some people watching this will try it without telling their prescriber, and if they regain weight or experience glucose dysregulation (especially relevant for anyone with type 2 diabetes), they may not connect it back to the changed dosing schedule.

She also implies that "working yourself back down" to a lower dose is a standard or common approach. There's no clinical consensus on this. The SCALE Maintenance trial for liraglutide (Pi-Sunyer et al., 2015, NEJM) and semaglutide data both suggest the drug needs to stay active, not just present at lower levels, to prevent regain. Dose reduction may work for some people, but it hasn't been systematically studied.

What should you actually know?

Maintenance on GLP-1 medications is a real and legitimate concern. The biology here is not subtle: these drugs suppress appetite and alter how your brain responds to food. When you stop, or likely when you drop below an effective threshold, those effects reverse. The body's weight-regulating systems push back hard.

If you're approaching your goal weight on semaglutide or tirzepatide, the conversation to have is with your prescriber, not TikTok. That conversation should cover what dose you actually need to maintain, whether your insurance covers long-term use, and what the off-ramp looks like if you do eventually stop. The interval-extension approach she describes may feel like it's working at 5 months, but that's not enough time to know whether it prevents regain over the 1-2 year window where the STEP extension data shows the most drift. Talk to your doctor before you start experimenting with your injection schedule.